Indivior Pharmaceuticals, Inc. (SUPN) · INSIDERData sourcesSEC Form 45h ago
House PTR5h ago
SEC 13F5h ago
Robinhood Chain5h ago
Public companyIndivior Pharmaceuticals, Inc.
SUPNCIK 0001625297
Price$26.16
1 year-18.4%
Disclosed transactions34
Buys / sells5 / 2
Max Insider Score41
Connections with evidence9
SUPN · disclosed activity on price
| Score | Actor | Security | Side | Value | Executed | Disclosed | Lag | Source | Evidence |
|---|
| 36 | ADAnderson Woodrow DChief Accounting Officer |  INDVIndivior Pharmaceuticals, Inc.Open-market purchase | BUY | $54K 1,500 sh | Aug 27, 2026 |
| Aug 27, 2026 traded Aug 27, 2026 |
| 20 | HCHeidbreder ChristianChief Scientific Officer | INDVIndivior Pharmaceuticals, Inc. Open-market sale · 10b5-1 plan | SELL | $707K 18.6K sh | Jun 11, 2026 | Jun 12, 2026 traded Jun 11, 2026 | +1d | SEC Form 4 | |
| 23 | PRPreblick RyanChief Financial Officer | INDVIndivior Pharmaceuticals, Inc. Open-market sale · 10b5-1 plan | SELL | $1.36M 36.0K sh | Jun 8, 2026 | Jun 10, 2026 traded Jun 8, 2026 | +2d | SEC Form 4 | |
| 17 | HKHumphreys KeithDirector | INDVIndivior Pharmaceuticals, Inc. Grant or award | A | — 6,518 sh | May 13, 2026 | May 14, 2026 traded May 13, 2026 | +1d | SEC Form 4 | |
| 17 | | INDVIndivior Pharmaceuticals, Inc. Grant or award | A | — 6,518 sh | May 13, 2026 | May 14, 2026 traded May 13, 2026 | +1d | SEC Form 4 | |
| 28 |  Gilbert Ray Cisneros, Jr.DSelf | SUPNIndivior Pharmaceuticals, Inc. Purchase | BUY | $1,001 – $15K | Mar 3, 2026 | Apr 7, 2026 traded Mar 3, 2026 | +35d | House PTR | |
| 9 | PRPreblick RyanChief Financial Officer | INDVIndivior Pharmaceuticals, Inc. Option exercise | M | — 6,302 sh | Mar 14, 2026 | Mar 17, 2026 traded Mar 14, 2026 | +3d | SEC Form 4 | |
| 12 | PRPreblick RyanChief Financial Officer | INDVIndivior Pharmaceuticals, Inc. Tax withholding | F | $88K 2,843 sh | Mar 14, 2026 | Mar 17, 2026 traded Mar 14, 2026 | +3d | SEC Form 4 | |
| 9 | PRPreblick RyanChief Financial Officer | INDVIndivior Pharmaceuticals, Inc. Option exercise | M | — 6,302 sh | Mar 14, 2026 | Mar 17, 2026 traded Mar 14, 2026 | +3d | SEC Form 4 | |
| 9 | PRPreblick RyanChief Financial Officer | INDVIndivior Pharmaceuticals, Inc. Option exercise | M | — 113.5K sh | Mar 3, 2026 | Mar 5, 2026 traded Mar 3, 2026 | +2d | SEC Form 4 | |
| 26 | HCHeidbreder ChristianChief Scientific Officer | INDVIndivior Pharmaceuticals, Inc. Tax withholding | F | $1.46M 45.8K sh | Mar 3, 2026 | Mar 5, 2026 traded Mar 3, 2026 | +2d | SEC Form 4 | |
| 9 | ADAnderson Woodrow DChief Accounting Officer | INDVIndivior Pharmaceuticals, Inc. Option exercise | M | — 5,946 sh | Mar 3, 2026 | Mar 5, 2026 traded Mar 3, 2026 | +2d | SEC Form 4 | |
| 9 | HCHeidbreder ChristianChief Scientific Officer | INDVIndivior Pharmaceuticals, Inc. Option exercise | M | — 132.6K sh | Mar 3, 2026 | Mar 5, 2026 traded Mar 3, 2026 | +2d | SEC Form 4 | |
| 16 | ADAnderson Woodrow DChief Accounting Officer | INDVIndivior Pharmaceuticals, Inc. Tax withholding | F | $86K 2,682 sh | Mar 3, 2026 | Mar 5, 2026 traded Mar 3, 2026 | +2d | SEC Form 4 | |
| 27 | ADAnderson Woodrow DChief Accounting Officer | INDVIndivior Pharmaceuticals, Inc. Tax withholding | F | $265K 8,283 sh | Mar 3, 2026 | Mar 5, 2026 traded Mar 3, 2026 | +2d | SEC Form 4 | |
| 21 | HCHeidbreder ChristianChief Scientific Officer | INDVIndivior Pharmaceuticals, Inc. Option exercise | M | — 101.5K sh | Mar 3, 2026 | Mar 5, 2026 traded Mar 3, 2026 | +2d | SEC Form 4 | |
| 21 | ADAnderson Woodrow DChief Accounting Officer | INDVIndivior Pharmaceuticals, Inc. Option exercise | M | — 18.4K sh | Mar 3, 2026 | Mar 5, 2026 traded Mar 3, 2026 | +2d | SEC Form 4 | |
| 17 | ADAnderson Woodrow DChief Accounting Officer | INDVIndivior Pharmaceuticals, Inc. Option exercise | M | — 5,946 sh | Mar 3, 2026 | Mar 5, 2026 traded Mar 3, 2026 | +2d | SEC Form 4 | |
| 9 | ADAnderson Woodrow DChief Accounting Officer | INDVIndivior Pharmaceuticals, Inc. Option exercise | M | — 24.0K sh | Mar 3, 2026 | Mar 5, 2026 traded Mar 3, 2026 | +2d | SEC Form 4 | |
| 30 | PRPreblick RyanChief Financial Officer | INDVIndivior Pharmaceuticals, Inc. Tax withholding | F | $2.80M 87.6K sh | Mar 3, 2026 | Mar 5, 2026 traded Mar 3, 2026 | +2d | SEC Form 4 | |
| 17 | PRPreblick RyanChief Financial Officer | INDVIndivior Pharmaceuticals, Inc. Option exercise | M | — 86.9K sh | Mar 3, 2026 | Mar 5, 2026 traded Mar 3, 2026 | +2d | SEC Form 4 | |
| 13 | PRPreblick RyanChief Financial Officer | INDVIndivior Pharmaceuticals, Inc. Grant or award | A | — 37.4K sh | Feb 10, 2026 | Feb 12, 2026 traded Feb 10, 2026 | +2d | SEC Form 4 | |
| 15 | ADAnderson Woodrow DChief Accounting Officer | INDVIndivior Pharmaceuticals, Inc. Grant or award | A | — 24.0K sh | Feb 9, 2026 | Feb 12, 2026 traded Feb 9, 2026 | +3d | SEC Form 4 | |
| 15 | HCHeidbreder ChristianChief Scientific Officer | INDVIndivior Pharmaceuticals, Inc. Grant or award | A | — 132.6K sh | Feb 9, 2026 | Feb 12, 2026 traded Feb 9, 2026 | +3d | SEC Form 4 | |
| 21 | ADAnderson Woodrow DChief Accounting Officer | INDVIndivior Pharmaceuticals, Inc. Grant or award | A | — 6,903 sh | Feb 10, 2026 | Feb 12, 2026 traded Feb 10, 2026 | +2d | SEC Form 4 | |
| 17 | HCHeidbreder ChristianChief Scientific Officer | INDVIndivior Pharmaceuticals, Inc. Grant or award | A | — 33.6K sh | Feb 10, 2026 | Feb 12, 2026 traded Feb 10, 2026 | +2d | SEC Form 4 | |
| 15 | PRPreblick RyanChief Financial Officer | INDVIndivior Pharmaceuticals, Inc. Grant or award | A | — 113.5K sh | Feb 9, 2026 | Feb 12, 2026 traded Feb 9, 2026 | +3d | SEC Form 4 | |
| 17 | | INDVIndivior Pharmaceuticals, Inc. Grant or award | A | — 3,722 sh | Jan 26, 2026 | Jan 28, 2026 traded Jan 26, 2026 | +2d | SEC Form 4 | |
| 21 | TJThompson JulietDirector | INDVIndivior Pharmaceuticals, Inc. Grant or award | A | — 3,722 sh | Jan 26, 2026 | Jan 28, 2026 traded Jan 26, 2026 | +2d | SEC Form 4 | |
| 17 | HKHumphreys KeithDirector | INDVIndivior Pharmaceuticals, Inc. Grant or award | A | — 3,722 sh | Jan 26, 2026 | Jan 28, 2026 traded Jan 26, 2026 | +2d | SEC Form 4 | |
| 13 | WEWheadon David E.Director | INDVIndivior Pharmaceuticals, Inc. Grant or award | A | — 5,955 sh | Jan 26, 2026 | Jan 28, 2026 traded Jan 26, 2026 | +2d | SEC Form 4 | |
| 33 | HKHumphreys KeithDirector | INDVIndivior Pharmaceuticals, Inc. Open-market purchase · 10b5-1 plan | BUY | $27K 775 sh | Jan 5, 2026 | Jan 7, 2026 traded Jan 5, 2026 | +2d | SEC Form 4 | |
| 36 | WEWheadon David E.Director | INDVIndivior Pharmaceuticals, Inc. Open-market purchase · 10b5-1 plan | BUY | $63K 1,771 sh | Jan 5, 2026 | Jan 7, 2026 traded Jan 5, 2026 | +2d | SEC Form 4 | |
| 41 | | INDVIndivior Pharmaceuticals, Inc. Open-market purchase · 10b5-1 plan | BUY | $27K 775 sh | Jan 5, 2026 | Jan 7, 2026 traded Jan 5, 2026 | +2d | SEC Form 4 | |
Chief Financial Officer · Feb 12, 2026